Search

Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer demonstrates selpercatinib’s marked antitumor activity in RET fusion-position non-small cell lung cancer (NSCLC) patients. These findings, presented by Alexander Drilon, MD, principal investigator and Research Director of Early Drug Development at Memorial Sloan Kettering Cancer Center, will form the basis of an US Food and Drug Administration new drug application submission.

… Monday, September 9, 2019 Bottom Line: Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer

The Gene: An Intimate History is a new four-hour documentary from the award-winning Ken Burns team and PBS, adapted from the award-winning book of the same name by Siddhartha Mukherjee, MD, DPhil. Memorial Sloan Kettering’s Luis Alberto Diaz, Jr., MD, Head of the Division of Solid Tumor Oncology, is a featured expert.

… Monday, April 13, 2020 The Gene: An Intimate History is a new four-hour documentary from the award-winning Ken Burns team and PBS, adapted from the award-winning book of the same name by Siddhartha Mukherjee, MD, DPhil. The two-part series brings to life a historical biography of the human genome while

By assuming primitive regenerative identities, cancer cells gain the adaptability they need to establish tumors in new parts of the body.

… Monday, February 10, 2020 Summary Scientists have discovered that cancer cells rely on the biology of regeneration, wound healing, and embryonic development to spread to other organs and escape detection by the immune system. Just as people tend to become stuck in their ways as they grow older so too

Research led by investigators at Memorial Sloan Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug, vemurafenib.

… Wednesday, November 23, 2011 Research led by investigators at Memorial Sloan Kettering Cancer Center has identified a previously unknown mechanism of resistance to the newly approved melanoma drug, vemurafenib, an oral targeted therapy used to treat advanced melanoma whose tumors contain a mutation in

Immunologist Alexander Rudensky and medical oncologist and immunologist Jedd Wolchok are investigating innovative ways to use the immune system to fight cancer.

… Monday, January 6, 2014 Summary Immunologist Alexander Rudensky and medical oncologist and immunologist Jedd Wolchok are investigating innovative ways to use the immune system to fight cancer. Memorial Sloan Kettering is one of six elite academic institutions to share an unprecedented total of $540 million

A multidisciplinary team at Memorial Sloan Kettering Cancer Center (MSK) has developed a proof-of-concept crisis ventilator intended to provide lifesaving breathing assistance to patients requiring it when more-sophisticated respiratory support equipment is unavailable.

… Thursday, April 23, 2020 VIDEO | 00:00:12 Crisis Vent The device acts like a mechanical hand to physically ‘bag’ ventilate an intubated patient. Video Details A multidisciplinary team at Memorial Sloan Kettering Cancer Center (MSK) has developed a proof-of-concept crisis ventilator intended to provide

GSK students, alumni, faculty, and guest speakers enjoyed two days of presentations, panel discussions, a poster session, recreation and socializing at the school’s fourth biennial retreat.

… Monday, June 6, 2016 MSK President and CEO Craig Thompson MSK President and CEO Craig Thompson gives a talk at the retreat about his work in cancer metabolism. GSK alumnus John Maciejowkski talks with GSK Dean Ken Marians and Charles Rudin GSK alumnus John Maciejowkski talks with GSK Dean Ken Marians

Medical oncologist Chau Dang explains that patients living with metastatic breast cancer have more treatment options than ever before.

… Thursday, October 27, 2016 Summary Metastatic breast cancer is a challenging disease to treat, and for that reason there are many efforts focused on helping patients to live longer and with fewer side effects. Thanks to advances in clinical care, patients with metastatic breast cancer have more treatment

Simon Powell leads the Department of Radiation Oncology and focuses in his research on the treatment of breast cancer, including the role of DNA repair deficiencies in breast cancer and breast cancer genetics.

… Friday, January 24, 2014 Summary Simon Powell leads the Department of Radiation Oncology and focuses in his research on the treatment of breast cancer, including the role of DNA repair deficiencies in breast cancer and breast cancer genetics. Simon Powell, Chair of the Department of Radiation Oncology

MSK is a founding member of Break Through Cancer, a newly launched foundation aimed at accelerating collaborative research, clinical trials, and cures for the deadliest cancers.

… Thursday, February 25, 2021 MSK today announced it is a founding member of Break Through Cancer , a newly launched foundation aimed at accelerating collaborative research, clinical trials, and cures for the deadliest cancers. The foundation is being launched with a $250 million matching gift challenge